CRSP CRISPR Therapeutics AG
CRSP CRISPR Therapeutics AG
Healthcare · Biotechnology
Desk view
Market read
Scan convergence 3 scans as of 2026-10-16 1 bear 2 neutral converging
POC $53.79 · VWAP $54.29 · -9.3% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster CEO, Director + 1 other sold $1.1M, Oct 8–16
Coverage
5 watchlists
CRSP Price Structure
Loading timeframes…
Peers
Every watchlist CRSP belongs to, members best 30-day change first — CRSP highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech
@ibb
@biotech-scan
@tech-insider-buys
@insider-universe
Reported the quarter ending 2026-06-30: revenue $10M, diluted EPS -$0.94, net income -$91M (SEC filing). Across the print the stock moved +10.6% (close before → first close after).
full note →Against street estimates
How CRSP's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about CRSP from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 2 days ago · Oct 15
- CRISPR Therapeutics AG (CRSP) Stock Price Today - WSJ
- Trade CRISPR Therapeutics (CRSP) Stock After-hours on Public.com
- Press Release Distribution and Management
- CRISPR Therapeutics Provides Business Update… | CRISPR Therapeutics
- CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
CRSP research tape
170 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.